News & Events

ISA Pharmaceuticals Appoints Ronald Loggers as Chief Executive Officer

July 07, 2014
Leiden, The Netherlands, July 07, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, to...
Read more

SomantiX and EdgeLeap team-up to mine new anti-angiogenesis targets for cancer therapy

July 02, 2014
SomantiX B.V. in Utrecht and the newly established data analysis company EdgeLeap B.V., founded by former TNO members will join...
Read more
SomantiX and EdgeLeap team-up to mine new anti-angiogenesis targets for cancer therapy

New Clinical Data Demonstrate Strong Synergy between Cancer Vaccine ISA101 and Chemotherapy

April 10, 2014
- Data presented at the AACR Annual Meeting 2014 - Potential new treatment being developed for patients with late-stage cervical cancer Leiden, The Netherlands, April 10, 2014 - ISA Pharmaceuticals B.V.,...
Read more

New Clinical Data on Cancer Vaccine ISA101 to Be Presented at the AACR Annual Meeting 2014

March 27, 2014
Leiden, The Netherlands, March 27, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections,...
Read more

ORCA Therapeutics granted Chinese Patent covering its T1 oncolytic adenovirus technology

March 22, 2014
Amsterdam, The Netherlands - March 20th, 2013 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has secured key intellectual pr...
Read more

ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology

March 04, 2014
- GlymaxX® Manufacturing Technology Improves Bispecific Antibody Activity for Solid Tumor Treatment - Berlin, Germany, and Utrecht, The Netherlands - March 4, 2014 - ProBioGen AG and Merus B.V. today anno...
Read more

ISA Pharmaceuticals Strengthens Patent Protection for its Lead Product ISA101

February 24, 2014
- Granted EU patent provides market exclusivity until 2028 - Leiden, The Netherlands, February 24, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed the...
Read more

Synthon Biopharmaceuticals ramping up for initiation of Phase I study with its frontrunner ADC SYD985

January 14, 2014
Nijmegen, the Netherlands, January 14, 2014 - In its quest to develop medications to treat serious diseases, Synthon Biopharmac...
Read more
Synthon Biopharmaceuticals ramping up for initiation of Phase I study with its frontrunner ADC SYD985

InteRNA Technologies, UCB and University of Bonn to collaborate on the role of microRNAs in neurodegenerative disease

January 10, 2014
Nijmegen/Utrecht (the Netherlands), January 10 2014 - InteRNA Technologies B.V., the Dutch biopharma company engaged in the development of microRNA (miRNA)-based therapeutics, and the Neuroallianz Consortium...
Read more

MiRacle Consortium led by InteRNA Technologies and VU University Medical Center Along with Quiet Therapeutics Receives a € 1.2 million FP7 Grant from the European Union

November 04, 2013
- Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer - acronym: MiRacle - Nijmegen/Utrecht and Amsterdam (the Netherla...
Read more

ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women with Cervical Cancer

October 29, 2013
- Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested together with chemotherapy in women with HPV16-positive advanced or recurrent cervical cancer - Leiden, The Netherlands, October 29...
Read more

Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies

October 23, 2013
- Invention provides unique technology base for therapeutic human bispecific antibodies - Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes Utrecht, The Netherl...
Read more

ISA Pharmaceuticals Establishes Advisory Board

October 15, 2013
- Renowned Specialists to Support Development of ISA's Advancing Pipeline - Leiden, The Netherlands, October 15, 2013 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationall...
Read more

Merus Secures €31 Million in Series B Round Extension

October 03, 2013
Investment brings Series B to a total of €47.6 million Johnson and Johnson Development Cooperation joins as new investor; receives board seat Utrecht, The Netherlands, October 3, 2013 - Merus B.V., a bioph...
Read more

ISA Pharmaceuticals Presents Novel Data at the European Cancer Congress 2013: Strong Synergies Between Cancer Vaccine ISA101 and Chemotherapy

September 30, 2013
Chemotherapy improves immune response to therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) Leiden, The Netherlands, September 30, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmac...
Read more

ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia (AIN)

September 16, 2013
Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested in HIV-positive male patients Leiden, The Netherlands, September 16, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceuti...
Read more

ORCA Therapeutics strengthens Scientific Advisory Board

September 05, 2013
Amsterdam, The Netherlands - September 3th, 2013 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its Scientific...
Read more

ISA Pharmaceuticals Strengthens Management Team

July 08, 2013
Company hires Jan Fagerberg as Chief Medical Officer and Jens Hennecke as Chief Business Officer Ronald Loggers becomes Acting Chief Executive Officer and Gerard Platenburg Chief Operating Officer Leiden, Th...
Read more

Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013

June 17, 2013
Clinical Candidate Designed for the Treatment of Acute Myeloid Leukemia (AML) Utrecht, The Netherlands, June 17, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeu...
Read more

SUPPRESTEM Consortium Led by Merus Receives €6 Million FP7 Grant from the European Union

May 27, 2013
Development of Therapeutic Bispecific Antibodies (Biclonics™) Targeting Treatment-resistant Cancer Stem Cells Using Patient-Derived Organoid Screening Tools Utrecht, The Netherlands, May 27, 2013 - Merus B....
Read more

Home > News & Events > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds